Vertex Pharmaceuticals — News Releases Biotech Press Releases — RSS Feed & Live Monitoring
PPN World tracks the Vertex Pharmaceuticals — News Releases RSS feed in real time — 3 releases indexed over the last 30 days, the newest arrived 6 d ago. Follow it with saved-search alerts, AI summaries, and full-text search, or plug the RSS URL below into your own reader.
Vertex Pharmaceuticals — News Releases RSS feed URL
https://investors.vrtx.com/rss/news-releases.xml?items=15About this feed
Vertex Pharmaceuticals — News Releases is one of the 1000+ press-release feeds PPN World monitors around the clock — an English-language wire focused on Biotech, filed under United States in our country index. Every release is deduplicated, geotagged, and enriched with an AI summary, and you can attach saved-search alerts to any keyword it publishes. Over the last 30 days Vertex Pharmaceuticals — News Releases has published 3 releases.
How to follow Vertex Pharmaceuticals — News Releases press releases
- Copy the Vertex Pharmaceuticals — News Releases RSS feed URL shown above.
- Paste it into any RSS reader (Feedly, Inoreader, NetNewsWire…) to get the raw feed.
- Or track Vertex Pharmaceuticals — News Releases in PPN World to add deduplication, saved-search alerts, and AI summaries across all 1000+ wires.
Latest Vertex Pharmaceuticals — News Releases press releases
- Vertex to Announce Second Quarter 2026 Financial Results on August 3rd6 d ago
BOSTON --(BUSINESS WIRE)--Jul. 7, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets…
- Vertex to Acquire Crinetics Pharmaceuticals7 d ago
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY ®, Crinetics’ recently launched, fi…
- Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia12 d ago
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional childr…
- Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions33 d ago
- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consist…
- Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference38 d ago
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of
- Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 1040 d ago
BOSTON --(BUSINESS WIRE)--Jun. 3, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr.…
- Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy42 d ago
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – BOSTON --(BUSINESS WIRE)--Jun. 1, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announc…
The newest releases on this wire stream live for PPN World members.